Reuters: Regulatory News: Baxter's Alzheimer's disease drug fails in late-stage trial

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Baxter's Alzheimer's disease drug fails in late-stage trial May 7th 2013, 11:29 Tue May 7, 2013 7:29am EDT May 7 (Reuters) - Baxter International Inc said a late-stage study of its experimental drug to treat Alzheimer's disease failed to reduce the decline of cognitive functions and preserve functional abilities. The trial showed that after 18 months of treatment, patients with mild to moderate Alzheimer's disease taking Baxter's immunoglobulin treatment did not show a statistically significant difference in the rate of cognitive decline compared to a placebo. The results also did not indicate a statistically significant change in patients' functional ability, Baxter said.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions